Unknown

Dataset Information

0

A Novel Antitumor Strategy: Simultaneously Inhibiting Angiogenesis and Complement by Targeting VEGFA/PIGF and C3b/C4b.


ABSTRACT: Therapeutic antibodies targeting vascular endothelial growth factor (VEGF) have become a critical regimen for tumor therapy, but the efficacy of monotherapy is usually limited by drug resistance and multiple angiogenic mechanisms. Complement proteins are becoming potential candidates for cancer-targeted therapy based on their role in promoting cancer progression and angiogenesis. However, the antitumor abilities of simultaneous VEGF and complement blockade were unknown. We generated a humanized soluble VEGFR-Fc fusion protein (VID) binding VEGFA/PIGF and a CR1-Fc fusion protein (CID) targeting C3b/C4b. Both VID and CID had good affinities to their ligands and showed effective bioactivities. In vitro, angiogenesis effects induced by VEGF and hemolysis induced by complement were inhibited by VID and CID, respectively. Further, VID and CID confer a synergetic therapeutic effect in a colitis-associated colorectal cancer (CAC) model and an orthotopic 4T1 breast cancer model. Mechanically, combination therapy inhibited tumor angiogenesis, cell proliferation, and MDSC infiltration in the tumor microenvironment and promoted tumor cell apoptosis. Our study offers a novel therapeutic strategy for anti-VEGF-resistant tumors and chronic-inflammation-associated tumors.

SUBMITTER: Wang H 

PROVIDER: S-EPMC6940616 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

A Novel Antitumor Strategy: Simultaneously Inhibiting Angiogenesis and Complement by Targeting VEGFA/PIGF and C3b/C4b.

Wang Huiling H   Li Yiming Y   Shi Gang G   Wang Yuan Y   Lin Yi Y   Wang Qin Q   Zhang Yujing Y   Yang Qianmei Q   Dai Lei L   Cheng Lin L   Su Xiaolan X   Yang Yang Y   Zhang Shuang S   Li Zhi Z   Li Jia J   Wei Yuquan Y   Yu Dechao D   Deng Hongxin H  

Molecular therapy oncolytics 20191214


Therapeutic antibodies targeting vascular endothelial growth factor (VEGF) have become a critical regimen for tumor therapy, but the efficacy of monotherapy is usually limited by drug resistance and multiple angiogenic mechanisms. Complement proteins are becoming potential candidates for cancer-targeted therapy based on their role in promoting cancer progression and angiogenesis. However, the antitumor abilities of simultaneous VEGF and complement blockade were unknown. We generated a humanized  ...[more]

Similar Datasets

| S-EPMC2223645 | biostudies-literature
| S-EPMC3265835 | biostudies-literature
| S-EPMC2189104 | biostudies-other
| S-EPMC1163378 | biostudies-other
| S-EPMC5041945 | biostudies-other
| S-EPMC4695159 | biostudies-literature
| S-EPMC10569063 | biostudies-literature
| S-EPMC7295066 | biostudies-literature
| S-EPMC4745744 | biostudies-literature
| S-EPMC7373746 | biostudies-literature